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Lindoso0000-0000-0000-0000 I,IV
I Instituto de Medicina Tropical, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR. II Escola Politecnica, Universidade de Sao
Paulo, Sao Paulo, SP, BR. IIIUniversity Hospitals Plymouth NHS Trust, Plymouth, England. IV Instituto de Infectologia Emilio Ribas, Sao Paulo, SP, BR.
Braz LMA, Tahmasebi R, Hefford PM, Lindoso JAL. Visceral Leishmaniasis diagnosis: a rapid test is a must at the hospital bedside. Clinics. 2020;75:e2036
*Corresponding author. E-mail: lmabraz@usp.br
At the time of the widespread availability of rapid
diagnostic tests for SARS-CoV-2—the causative virus of the
COVID-19 pandemic—from drugstores throughout Brazil,
there is a distinct lack of use of rapid diagnostic tests for
visceral leishmaniasis (VL) at the bedsides of hospitalized
patients. These tests are mainly distributed by the Ministério
da Saúde do Brazil-MS (Ministry of Health) only to the
Laboratórios Centrais de Saúde Publica - LACENs (Central
Public Health Laboratories) and are predominantly provided
to public hospitals.
VL is the most severe form of leishmaniasis and it causes
high morbidity and mortality in developing countries (1,2).
Leishmania infantum chagasi is responsible for VL in the
New World, with typical clinical signs and symptoms of sple-
nomegaly, hepatomegaly, and fever (3). VL can be life-
threatening, and because 90% cases of VL occur in Brazil,
reliable and rapid diagnosis of VL is required (4).
As stated by the MS, VL case confirmation is based on
clinical suspicion and positive laboratory diagnosis via either
parasitological tests (PTs), which are dependent on invasive
procedures such as bone marrow aspiration or biopsy, or
serological tests such as indirect immunofluorescence (IFI) or
immunochromatographic tests (ITs) using rK39 recombinant
antigens (5). The serological tests IFI and IT-rK39 have the
advantage of being minimally invasive and they can be
performed in large numbers (6).
However, IFI requires a fluorescence microscope and is
time consuming. The procedure of IT-rK39 takes only 10–15
minutes and requires only 10–20 mL of the peripheral blood.
It is a rapid and low-cost bedside test. The rK39 dipstick used
for ITs is the product of a gene cloned from the Leishmania
genus containing a 39-amino acid repeat conserved among
viscerotropic Leishmania species (7).
The main brands of IT-rK39 that were previously provided
by the Brazilian public health system consisted of Kalazar
Detectt (InBios International, Seattle, WA, USA), IT LEISHs
(BIO-RAD Laboratories Inc., France), and OnSitet Leishma-
nia IgG/IgM Combo test (CTK Biotech, USA), which have
now been replaced with the LSH Ab ECO test (Eco
Diagnóstica, Nova Lima, MG, Brasil). Kalazar Detectt was
the first rapid test for VL diagnosis that was adopted by the
Brazilian public health system in 2009. It has a sensitivity and
specificity of 88.1% and 90.6%, respectively.
In 2015, IT LEISHs replaced the Kalazar Detectt and
showed an improved sensitivity and specificity of 93% and
97%, respectively (8). However, these IT-rK39 tests would
usually present a lower accuracy when tested in patients
coinfected with HIV (9,10).
In 2017, the OnSitet Leishmania IgG/IgM Combo test
replaced the IT LEISHs (8). Today, MS recommends using a
new brand, the LSH Ab ECO test, a qualitative immunoassay
for the detection of antibodies (rK39) against VL in human
serum (11). The specificity for this test is equal to 100% (95%
CI 0.93-1), indicating that it has high specificity for the rK39
protein. The sensitivity presented by the LSH Ab ECO is 92%
(95% CI 0.82-0.97) (11).
LSH Ab ECO test was declared by the Agência Nacional
de Vigilância Sanitária-ANVISA (National Health Surveil-
lance Agency) as a criterion for the laboratory confirmation
of suspected cases of the disease. Therefore, suspicious patients,
including those presenting with clinical signs compatible with
disease and those coming from a region with known occur-
rence of transmission, alongside a positive rapid test, can be
considered confirmed cases of VL based on clinical labora-
tory criteria.
The LSH Ab ECO test has technical specifications and
execution methodology similar to those of the brands used
before. According to the manufacturer, LSH Ab ECO, a
lateral flow chromatographic immunoassay used to detect
class G immunoglobulin for Leishmania donovani, uses recom-
binant antigens in the test line and chicken anti-protein A in
the control line. It is easy to use and interpret. In accordance
with the manufacturer’s instructions and technical orienta-
tion from SDP/IOM/FUNED no001/2019 (12), the procedure
of the test is as follows: add 20 mL of serum/plasma or 1 drop
of blood (10 mL) to the test strip pad, below the arrows. If
serum, plasma, or blood is applied to the test strip hori-
zontally on a flat surface, take the strip by the green label and
place it vertically, with the arrow pointing downwards, in a
test tube or microwell containing 2–3 drops (150 mL) of the
diluent buffer. If serum, plasma, or blood is applied to the
test strip vertically, add 2–3 drops (150 mL) of the diluentDOI: 10.6061/clinics/2020/e2036
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buffer to the base of the microwell or test tube and read the
test result after 10 minutes.
It is important to highlight that this IT for rK39 is
produced by a Brazilian biotechnology industry located in
the state of Minas Gerais, Brazil, as the previously used
brands were produced by industries situated outside of Brazil.
This is an important achievement for the Brazilian health
system with regard to VL diagnosis.
In summary, the test is suitable for use at the bedside,
requires a minimal amount (10 mL) of peripheral blood, with
no need of special equipment, and is simple to perform and
read, with the results being available in 10 minutes.
However, this simple dipstick test for rK39, distributed by
the Ministério da Saúde do Brazil to public laboratories, is
not available in some public hospitals, including Hospital
das Clinicas da Faculdade de Medicina da Universidade de
São Paulo (HCFMUSP). Rapid test-rK39 is not even offered
by the majority of private laboratories and private hospitals
for VL diagnosis. Even if it is provided, the turnaround time
between sending the sample and receiving results is typically
a minimum of 24 hours; thus, it can hardly be deemed as a
‘rapid test’ with any conviction.
It is time to change the narrative and alter the distributive
flowchart of this test. It is necessary to use the rK39 IT at
the bedside of suspected VL patients across hospitals to
the greatest effect. Why not employ the technical skills of a
team who usually attend patient needs, such as nurses and
nursing technicians, thereby ensuring that the rK39 IT truly
does indeed become a rapid diagnostic bedside test? VL
can be lethal and patients simply cannot afford to wait for
diagnoses/treatments.
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